Which is the highest rated weight loss injection available in the UK?

The case for Mounjaro: why the dual-receptor approach matters

Mounjaro is the only weight-loss injection licensed in the UK that targets two gut-hormone receptors simultaneously. By activating both GIP and GLP-1 pathways, it slows how quickly the stomach empties and amplifies signals of fullness in ways that a single-receptor medicine cannot fully replicate. That biological difference shows up in the numbers.

In SURMOUNT-1, a 72-week randomised trial involving 2,539 adults with obesity and no diabetes, participants taking the highest dose lost an average of around 20–21% of their body weight. The full SURMOUNT-1 results are published in the New England Journal of Medicine and formed the basis for NICE's recommendation of tirzepatide (TA1026, published December 2024). In a subsequent head-to-head trial, SURMOUNT-5, tirzepatide produced greater average weight reduction than semaglutide 2.4mg over 72 weeks, the first time the two had been compared directly in a large randomised setting.

Mounjaro is delivered once a week via a pre-filled KwikPen. Treatment starts at 2.5mg (a dose that exists to let your body adjust, rather than to produce weight loss from day one) and the prescriber titrates upward through six licensed strengths (2.5, 5, 7.5, 10, 12.5 and 15mg). If you want a broader overview of what the injection involves day-to-day, the guide to weight loss injections on this site covers the practical side in detail. Storage matters too: Mounjaro must be refrigerated between 2–8°C, and if you are unsure about the rules around temperature and travel, our page on whether weight loss injections need to be refrigerated explains exactly what you need to know, because getting it wrong affects the medicine's stability.

NICE recommends tirzepatide for adults with a BMI of 35 or above plus at least one weight-related comorbidity, with lower thresholds applying for some ethnic backgrounds under UK guidance. Private licensed eligibility is somewhat broader: BMI of 30 or above, or 27 with a qualifying condition such as high blood pressure, type 2 diabetes or obstructive sleep apnoea.

The case for Wegovy: an established track record and a new higher dose

Wegovy has been available in the UK longer than Mounjaro and has a well-documented real-world profile. The STEP 1 trial (68 weeks, semaglutide 2.4mg) showed an average weight reduction of around 15%, and the NHS semaglutide medicines page summarises what patients can expect alongside a clear account of common side effects.

The bigger development is the 7.2mg dose. The MHRA approved a dedicated single-dose 7.2mg Wegovy pen in April 2026, one pre-set weekly injection, with a built-in covered needle that locks after use. Trial results at this higher dose showed average weight loss of around 20.7% over 72 weeks, closing the gap with Mounjaro's highest-dose results considerably. The titration schedule still begins at 0.25mg, with the prescriber stepping up roughly every four weeks to a maximum of 7.2mg.

For people who are needle-cautious, it is worth checking the injection mechanism before committing: both pens are designed to make the process as straightforward as possible, but spending sixty seconds watching the manufacturer's video demonstration is the kind of quick habit that removes a lot of anxiety before the first dose. Proper injection-site rotation (abdomen, thigh or upper arm) and good technique reduce the chance of skin reactions at the site.

Wegovy also holds a NICE recommendation (TA875), though with more restrictive NHS conditions than tirzepatide, including a maximum treatment duration of two years within a specialist weight management service.

Side effects: what the two injections share, and where they differ

The side-effect profiles overlap substantially because both medicines slow gastric emptying. Nausea is the most commonly reported effect, followed by constipation, diarrhoea, indigestion and fatigue. These tend to be most noticeable in the first few weeks or after a dose increase, and settle as the body adapts for most people.

In January 2026 the MHRA issued a Drug Safety Update specifically on GLP-1 medicines, highlighting acute pancreatitis as an infrequent but potentially serious risk. The warning signs (severe stomach pain that reaches through to the back, sometimes with vomiting) warrant urgent medical attention rather than waiting to see if they pass. Anyone experiencing those symptoms should contact a doctor or call 111 promptly.

For women using oral contraceptives, tirzepatide carries a specific interaction note: because it slows gastric emptying, pill absorption may be reduced during the first four weeks of treatment and for four weeks after each dose increase. Adding a non-oral method such as condoms during those windows is the standard advice. The same concern has not been established for semaglutide. If HRT is part of your routine, the transdermal route (patches or gels) sidesteps the absorption question entirely, worth raising with your prescriber if relevant.

If you have questions about a specific side effect or situation, the FAQs section covers the queries our prescribers hear most regularly.

Making the decision: private access and how clinical review works

Neither injection is available without a prescription in the UK. The practical question for most people reading this is whether to wait for NHS access (which is governed by strict phased eligibility criteria under NICE TA1026 and TA875) or to pursue a private prescription through a regulated pharmacy.

For context on what private treatment costs in the UK, the treatment overview page lays out what is included in a private prescription route and what to look for in a provider. Price should not be the primary factor for a Prescription-Only Medicine, the credentials of the pharmacy and the rigour of the clinical review matter more, and reading about the best rated weight loss injections currently available can help you understand what standards a reputable provider should meet. Any legitimate online pharmacy can be confirmed on the GPhC register at pharmacyregulation.org.

At nume, every consultation is read by a GPhC-registered Independent Prescriber (a real clinician, not automated software) and prescriptions are only issued where the evidence of clinical suitability is clear. Our prescribers consider your full health history, any medicines you already take, and your weight-related conditions before recommending which injection, if either, is appropriate for you, and if you are exploring newer approaches such as stem cell injection for weight loss, they can help you understand where the evidence currently stands. You can read about our clinical team's approach on the clinical team page.

The distinction between these two injections is real and clinically meaningful. Which one suits you is a decision made together with a prescriber, not determined by trial headlines alone. If you are ready to find out which option fits your situation, our guides to top rated weight loss injections and to finding top rated weight loss injections near me can help you take the next step, or you can go straight to check your eligibility with our free consultation.